BR112014014492B1 - Peptídeos modificados ou sais dos mesmos, composição e composição farmacêutica compreendendo os referidos peptídeos, bem como uso da composição farmacêutica para tratar doenças autoimunes - Google Patents

Peptídeos modificados ou sais dos mesmos, composição e composição farmacêutica compreendendo os referidos peptídeos, bem como uso da composição farmacêutica para tratar doenças autoimunes Download PDF

Info

Publication number
BR112014014492B1
BR112014014492B1 BR112014014492-3A BR112014014492A BR112014014492B1 BR 112014014492 B1 BR112014014492 B1 BR 112014014492B1 BR 112014014492 A BR112014014492 A BR 112014014492A BR 112014014492 B1 BR112014014492 B1 BR 112014014492B1
Authority
BR
Brazil
Prior art keywords
peptide
seq
composition
amino acid
pharmaceutical composition
Prior art date
Application number
BR112014014492-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014014492A2 (pt
Inventor
Sylviane Muller
Jean-Paul Briand
Robert Zimmer
Original Assignee
Centre National De La Recherche Scientifique
Immupharma France Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Immupharma France Sa filed Critical Centre National De La Recherche Scientifique
Publication of BR112014014492A2 publication Critical patent/BR112014014492A2/pt
Publication of BR112014014492B1 publication Critical patent/BR112014014492B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
BR112014014492-3A 2011-12-13 2011-12-13 Peptídeos modificados ou sais dos mesmos, composição e composição farmacêutica compreendendo os referidos peptídeos, bem como uso da composição farmacêutica para tratar doenças autoimunes BR112014014492B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/003256 WO2013088194A1 (en) 2011-12-13 2011-12-13 Modified peptides and their use for treating autoimmune diseases

Publications (2)

Publication Number Publication Date
BR112014014492A2 BR112014014492A2 (pt) 2020-10-27
BR112014014492B1 true BR112014014492B1 (pt) 2022-05-24

Family

ID=45607295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014492-3A BR112014014492B1 (pt) 2011-12-13 2011-12-13 Peptídeos modificados ou sais dos mesmos, composição e composição farmacêutica compreendendo os referidos peptídeos, bem como uso da composição farmacêutica para tratar doenças autoimunes

Country Status (14)

Country Link
US (2) US9657072B2 (https=)
EP (2) EP2790715B1 (https=)
JP (1) JP6060175B2 (https=)
KR (2) KR20170020556A (https=)
CN (2) CN106986927A (https=)
AU (2) AU2011383222C1 (https=)
BR (1) BR112014014492B1 (https=)
CA (1) CA2858957C (https=)
DK (2) DK2790715T3 (https=)
ES (1) ES2618402T3 (https=)
HU (1) HUE032552T2 (https=)
IN (1) IN2014MN01376A (https=)
RU (1) RU2620070C2 (https=)
WO (1) WO2013088194A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213482B2 (en) * 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
CN109312379B (zh) 2016-04-05 2022-04-12 科学与工业研究委员会 多功能重组核苷酸依赖性糖基转移酶蛋白及其糖基化的方法
WO2018109285A1 (fr) * 2016-12-13 2018-06-21 Centre National De La Recherche Scientifique Peptides pour le traitement du neurolupus
WO2021198135A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
DK1425295T3 (da) * 2001-09-06 2010-05-03 Centre Nat Rech Scient Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme
FR2829768B1 (fr) 2001-09-18 2003-12-12 Centre Nat Rech Scient Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
EP2450368A1 (en) * 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs

Also Published As

Publication number Publication date
EP3202413A1 (en) 2017-08-09
KR101728784B1 (ko) 2017-04-21
CN104114180B (zh) 2017-01-18
JP6060175B2 (ja) 2017-01-11
DK3202413T3 (en) 2018-11-19
CA2858957A1 (en) 2013-06-20
RU2014128612A (ru) 2016-02-10
US9657072B2 (en) 2017-05-23
DK2790715T3 (en) 2017-03-20
AU2011383222C1 (en) 2017-04-20
ES2618402T3 (es) 2017-06-21
EP2790715A1 (en) 2014-10-22
CA2858957C (en) 2019-09-03
US20150111835A1 (en) 2015-04-23
AU2017200207B2 (en) 2018-03-01
WO2013088194A1 (en) 2013-06-20
IN2014MN01376A (https=) 2015-04-17
AU2017200207A1 (en) 2017-02-02
KR20140114365A (ko) 2014-09-26
BR112014014492A2 (pt) 2020-10-27
AU2011383222B2 (en) 2016-10-27
US20170226167A1 (en) 2017-08-10
RU2620070C2 (ru) 2017-05-22
CN106986927A (zh) 2017-07-28
HUE032552T2 (en) 2017-09-28
KR20170020556A (ko) 2017-02-22
CN104114180A (zh) 2014-10-22
EP3202413B1 (en) 2018-08-01
EP2790715B1 (en) 2016-12-07
JP2015501831A (ja) 2015-01-19
AU2011383222A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
EP3389692B1 (en) Modulators of complement activity
JP2018512401A (ja) Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
AU2017200207B2 (en) Modified peptides and their use for treating autoimmune diseases
CN107454846B (zh) 修饰的肽及其治疗慢性炎性疾病的用途
KR20160124236A (ko) 만성 폐 동종이식편 기능이상 및 특발성 폐 섬유증의 예방 또는 치료를 위한 조성물 및 방법
KR20170044171A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
del Río Oliva Targeting the immunoproteasome and VCP/p97 in autoimmune disorders and viral infection
JP2025538191A (ja) 融合ポリペプチドの製造方法
BR112018012174B1 (pt) Composição farmacêutica que compreende um polipeptídeo inibidor de c5, kit, dispositivo de auto injetor e uso
HK40031446A (en) Modulators of complement activity
HK40031446B (en) Modulators of complement activity
EA021643B1 (ru) Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/12/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; IMMUPHARMA FRANCE SA (FR)

B25D Requested change of name of applicant approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; IMMUPHARMA BIOTECH SAS (FR)